Role of BET Bromodomain in Hematopoietic Differentiation from hESCs.
- Author:
Zi-Cen FENG
1
;
Yu-Qi WEN
1
;
Meng-Ge WANG
1
;
Qian TU
1
;
Hong-Tao WANG
1
;
Zheng-Yu WANG
2
;
Jia-Xi ZHOU
3
Author Information
- Publication Type:Journal Article
- MeSH: Apelin Receptors; Cell Differentiation; Flow Cytometry; Hemangioblasts; Hematopoietic Stem Cells; Human Embryonic Stem Cells; Humans
- From: Journal of Experimental Hematology 2018;26(4):1186-1193
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the role of bromodomain and extra terminal (BET) bromodomain in hematopoietic differentiation from human enbryonic stem cells (hESC).
METHODSThe effect of BET hematopoietic inhibitor I-BET151 on hematopoietic differentiation from hESC was detected by using a monolayer hematopoietic defferentiation model, immunofluorescence, flow cytometry and real-time PCR; moreover the role of I-BET151 in process of hematopoietic differentiation was explored by adding I-BET151 in different differentiation stages.
RESULTSThe analysis results of immunofluorescence, flow cytometry and real-time PCR showed that I-BET 151 significantly inhibited the generation of CD43 positive hematopoietic stem and progenitor cells (HSPCs). It was found that the addition of I-BET 151 in different stages, including APLNR lateral plate mesoderm production, CD34CD31 hemogenic endothelium (HEP) generation and endothelial-to-hematopoietic transition, significantly suppressed the generation of CD43 positive hematopoietic progenitor cells.
CONCLUSIONI-BET 151 inhibites hematopoietic differentiation from hESCs at several stages, suggesting that the BET bromodomain plays important roles in multiple stages of hematopoietic differentiation from hESCs.
